Cited by 643Prostate Cancer Treatment and ResearchChromatin Remodeling and CancerHormonal and reproductive studies

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Open access

Watson, Philip A., Chen, Yinan F., Balbas, Minna D., Wongvipat, John, Socci, Nicholas D., Viale, Agnes, Kim, Kwanghee, Sawyers, Charles L.·2010·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1012443107PMC PMC2947883

Open this paper in CoChat — free account

Abstract

Androgen receptor (AR) splice variants lacking the ligand binding domain (ARVs), originally isolated from prostate cancer cell lines derived from a single patient, are detected in normal and malignant human prostate tissue, with the highest levels observed in late stage, castration-resistant prostate cancer. The most studied variant (called AR-V7 or AR3) activates AR reporter genes in the absence of ligand and therefore, could play a role in castration resistance. To explore the range of potential ARVs, we screened additional human and murine prostate cancer models using conventional and next generation sequencing technologies and detected several structurally diverse AR isoforms. Some, like AR-V7/AR3, display gain of function, whereas others have dominant interfering activity. We also find that ARV expression increases acutely in response to androgen withdrawal, is suppressed by testosterone, and in some models, is coupled to full-length AR (AR-FL) mRNA production. As expected, constitutively active, ligand-independent ARVs such as AR-V7/AR3 are sufficient to confer anchorage-independent (in vitro) and castration-resistant (in vivo) growth. Surprisingly, this growth is blocked by ligand binding domain-targeted antiandrogens, such as MDV3100, or by selective siRNA silencing of AR-FL, indicating that the growth-promoting effects of ARVs are mediated through AR-FL. These data indicate that the increase in ARV expression in castrate-resistant prostate cancer is an acute response to castration rather than clonal expansion of castration or antiandrogen-resistant cells expressing gain of function ARVs, and furthermore, they provide a strategy to overcome ARV function in the clinic.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.1012443107

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

TopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L. S., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,682
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Self-citation
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M., Efstathiou, E., Rathkopf, D. E., Shelkey, J., Yu, E. Y., Alumkal, J. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Self-citation
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
FXXLF and WXXLF Sequences Mediate the NH2-terminal Interaction with the Ligand Binding Domain of the Androgen Receptor
He, B., Kemppainen, J., & Wilson, E. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002807200 · Cited by 441
Molecular basis of androgen insensitivity
Brinkmann, A. O. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00466-x · Cited by 345

Show all 27 references

Sorted by citations

Items 201–300 of 643

A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities
Kounatidou, E. E., Nakjang, S., McCracken, S. R., Dehm, S. M., Robson, C. N., Jones, D. L., & Gaughan, L. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz286 · Cited by 52
The role of DAB2IP in androgen receptor activation during prostate cancer progression
Wu, K., Liu, J., Tseng, S.-F., O’Brien-Gore, C., Ning, Z., Sharifi, N., Fazli, L., Gleave, M. E., Kapur, P., Xiao, G., et al. (2013) · Oncogene · doi:10.1038/onc.2013.143 · Cited by 51
A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland
Pakula, H., Xiang, D., & Li, Z. (2017) · Cancers · doi:10.3390/cancers9020014 · Cited by 55
Allosteric interactions prime androgen receptor dimerization and activation
Wasmuth, E. V., Broeck, A. V., LaClair, J. R., Hoover, E. A., Lawrence, K. E., Paknejad, N., Pappas, K., Matthies, D., Wang, B., Feng, W., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.03.035 · Cited by 50
“FL ERG repressed activity of an AR variant lacking the N-terminus, but exerted no effect on AR V7, a splice isoform lacking the LBD that is expressed in CRPC patients and associated with anti-androgen resistance (Watson et al., 2010) (Fig.”
Background
Targeting the androgen receptor signalling axis in castration‐resistant prostate cancer (CRPC)
Tsao, C., Galsky, M. D., Small, A., Yee, T., & Oh, W. K. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11445.x · Cited by 51
Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth
Kach, J., Long, T. M., Selman, P., Tonsing-Carter, E. Y., Bacalao, M. A., Lastra, R. R., de Wet, L., Comiskey, S., Gillard, M., VanOpstall, C., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0923 · Cited by 50
Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer
Khurana, N., Kim, H., Chandra, P. K., Talwar, S., Sharma, P., Abdel‐Mageed, A. B., Sikka, S. C., & Mondal, D. (2017) · Oncology Reports · doi:10.3892/or.2017.5932 · Cited by 49
Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer
Dalal, K., Ban, F., Li, H., Morin, H., Roshan‐Moniri, M., Tam, K. J., Shepherd, A., Sharma, A., Peacock, J. W., Carlson, M. L., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.016 · Cited by 51
Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG
Wasmuth, E. V., Hoover, E. A., Antar, A., Klinge, S., Chen, Y., & Sawyers, C. L. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922159117 · Cited by 50
Androgen receptor variation affects prostate cancer progression and drug resistance
McCrea, E. M., Sissung, T. M., Price, D. K., Chau, C. H., & Figg, W. D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.001 · Cited by 49
Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Dong, J., Wu, Z., Wang, D., Pascal, L. E., Nelson, J. B., Wipf, P., & Wang, Z. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0432 · Cited by 49
“B, C4-2 cells were transfected with expression vectors for GFP-tagged NTD, AR(1-293), and AR(294-556), along”
BackgroundMethod
MiR-644a Disrupts Oncogenic Transformation and Warburg Effect by Direct Modulation of Multiple Genes of Tumor-Promoting Pathways
Ebron, J. S., Shankar, E., Singh, J., Sikand, K., Weyman, C. M., Gupta, S., Lindner, D. J., Liu, X., Campbell, M. J., & Shukla, G. C. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2993 · Cited by 49
The transcriptional programme of the androgen receptor ( AR ) in prostate cancer
Lamb, A. D. G., Massie, C. E., & Neal, D. E. (2013) · British Journal of Urology · doi:10.1111/bju.12415 · Cited by 48
Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives
Nadiminty, N., & Gao, A. C. (2011) · World Journal of Urology · doi:10.1007/s00345-011-0771-3 · Cited by 49
Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells
Sarwar, M., Semenas, J., Рифкатовна, М. Р., Simoulis, A., Robinson, B. D., Wingren, A. G., Mongan, N. P., Heery, D. M., Johnsson, H., Abrahamsson, P.-A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11757 · Cited by 49
Regulation of PCGEM1 by p54/nrb in prostate cancer
Ho, T.-T., Huang, J., Zhou, N., Zhang, Z., Koirala, P., Zhou, X., Wu, F., Ding, X., & Mo, Y. (2016) · Scientific Reports · doi:10.1038/srep34529 · Cited by 49
Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity
Giridhar, P. V., Williams, K., VonHandorf, A., Deford, P. L., & Kasper, S. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1753 · Cited by 48
Androgen Receptor in Breast Cancer: From Bench to Bedside
Chen, M., Yang, Y., Xu, K., Li, L., Huang, J., & Qiu, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00573 · Cited by 49
JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells
Laschak, M., Spindler, K., Schrader, A. J., Hessenauer, A., Streicher, W., Schrader, M. G., & Cronauer, M. V. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-130 · Cited by 47
Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
Kobayashi, T., Inoue, T., Kamba, T., & Ogawa, O. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140815615 · Cited by 47
Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer
Zhang, Y., Castaneda, S., Dumble, M. L., Wang, M., Mileski, M., Qu, Z., Kim, S., Shi, V., Kraft, P., Gao, Y. J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0329 · Cited by 47
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations
Lu, C., Brown, L. C., Antonarakis, E. S., Armstrong, A. J., & Luo, J. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0217-3 · Cited by 48
Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression
Schrecengost, R. S., Keller, S. N., Schiewer, M. J., Knudsen, K. E., & Smith, C. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0626 · Cited by 48
Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients
Li, H., Wang, Z., Xiao, W., Yan, L., Guan, W., Hu, Z., Wu, L., Huang, Q., Wang, J., Xu, H., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.74 · Cited by 47
Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer
Martens‐Uzunova, E. S., Kusuma, G. D., Crucitta, S., Lim, H. K., Cooper, C., Riches, J. D., Azad, A., Ochiya, T., Boyle, G. M., Southey, M. C., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12136 · Cited by 46
Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer
Martin, S. K., & Kyprianou, N. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.03.001 · Cited by 48
Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis
Li, H., Wang, Z., Tang, K., Zhou, H., Liu, H., Yan, L., Guan, W., Chen, K., Xu, H., & Ye, Z. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.01.004 · Cited by 46
Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T
Dorff, T. B., Hirasawa, Y., Acoba, J. D., Pagano, I., Tamura, D. J., Pal, S. K., Zhang, M., Waitz, R., Dhal, A., Haynes, W. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002931 · Cited by 49
Targeting the Androgen Receptor in Prostate Cancer — A Resilient Foe
Nelson, P. S. (2014) · New England Journal of Medicine · doi:10.1056/nejme1409306 · Cited by 46
Differential Expression of the Androgen-Conjugating UGT2B15 and UGT2B17 Enzymes in Prostate Tumor Cells during Cancer Progression
Pâquet, S., Fazli, L., Grosse, L., Verreault, M., Têtu, B., Rennie, P. S., Bélanger, A., & Barbier, O. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2064 · Cited by 44
Natural Products for the Management of Castration-Resistant Prostate Cancer: Special Focus on Nanoparticles Based Studies
Singla, R. K., Chandragiri, S. S., Chopra, H., Behzad, S., Bansal, H., Goyal, R., Gautam, R. K., Tsagkaris, C., Joon, S., Singla, S., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.745177 · Cited by 44
Interplay Between Genomic Alterations and Androgen Receptor Signaling During Prostate Cancer Development and Progression
Nyquist, M. D., & Dehm, S. M. (2013) · Hormones and Cancer · doi:10.1007/s12672-013-0131-4 · Cited by 44
Development of the external genitalia: Perspectives from the spotted hyena (Crocuta crocuta)
Cunha, G. R., Risbridger, G. P., Wang, H., Place, N. J., Grumbach, M. M., Cunha, T. J., Weldele, M. L., Conley, A. J., Barcellos, D., Agarwal, S., et al. (2014) · Differentiation · doi:10.1016/j.diff.2013.12.003 · Cited by 43
Food components and contaminants as (anti)androgenic molecules
Marcoccia, D., Pellegrini, M., Fiocchetti, M., Lorenzetti, S., & Marino, M. (2017) · Genes & Nutrition · doi:10.1186/s12263-017-0555-5 · Cited by 43
Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
Kim, T. J., Lee, Y. H., & Koo, K. C. (2021) · Biomolecules · doi:10.3390/biom11040492 · Cited by 43
PSA regulates androgen receptor expression in prostate cancer cells
Saxena, P., Trerotola, M., Wang, T., Li, J., Sayeed, A., VanOudenhove, J., Adams, D. S., FitzGerald, T. J., Altieri, D. C., & Languino, L. R. (2011) · The Prostate · doi:10.1002/pros.21482 · Cited by 41
FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants
Bohrer, L. R., Liu, P., Zhong, J., Pan, Y., Angstman, J. F., Brand, L. J., Dehm, S. M., & Huang, H. (2013) · The Prostate · doi:10.1002/pros.22649 · Cited by 41
Androgen Receptor Gene Rearrangements: New Perspectives on Prostate Cancer Progression
Brand, L. J., & Dehm, S. M. (2013) · Current Drug Targets · doi:10.2174/1389450111314040005 · Cited by 42
Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
Luo, J. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.178490 · Cited by 41
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer
Maity, S. N., Titus, M. A., Gyftaki, R., Wu, G., Lu, J.-F., Ramachandran, S., Li-Ning-Tapia, E. M., Logothetis, C. J., Araujo, J. C., & Efstathiou, E. (2016) · Scientific Reports · doi:10.1038/srep35354 · Cited by 39
Crosstalk between the Androgen Receptor and PPAR Gamma Signaling Pathways in the Prostate
Olokpa, E., Moss, P. E., & Stewart, L. V. (2017) · PPAR Research · doi:10.1155/2017/9456020 · Cited by 37
Understanding extranuclear (nongenomic) androgen signaling: What a frog oocyte can tell us about human biology
Sen, A., Prizant, H., & Hammes, S. R. (2011) · Steroids · doi:10.1016/j.steroids.2011.02.016 · Cited by 38
Enzalutamide: Development from bench to bedside
Bambury, R. M., & Scher, H. I. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.12.017 · Cited by 39
Clonal origin and spread of metastatic prostate cancer
Etten, J. L. V., & Dehm, S. M. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0049 · Cited by 40
miR‐103a‐2‐5p/miR‐30c‐1‐3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7
Chen, W., Yao, G., & Zhou, K.-Q. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28680 · Cited by 38
20(S)-Protopanaxadiol Inhibition of Progression and Growth of Castration-Resistant Prostate Cancer
Cao, B., Qi, Y., Yang, Y., Liu, X., Xu, D., Guo, W., Zhan, Y., Xiong, Z., Zhang, A., Wang, A. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111201 · Cited by 38
Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
Guedes, L. B., Morais, C. L., Almutairi, F., Haffner, M. C., Zheng, Q., Isaacs, J. T., Antonarakis, E. S., Lu, C., Tsai, H. K., Luo, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0205 · Cited by 38
NF‐κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance
Austin, D. C., Strand, D. W., Love, H. L., Franco, O. E., Grabowska, M. M., Miller, N. L., Hameed, O. M., Clark, P. E., Matusik, R. J., Jin, R. J., et al. (2016) · The Prostate · doi:10.1002/pros.23195 · Cited by 37
Complex Impacts of PI3K/AKT Inhibitors to Androgen Receptor Gene Expression in Prostate Cancer Cells
Liu, L., & Dong, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108780 · Cited by 37
Age- and Sex-Dependent Changes in Androgen Receptor Expression in the Developing Mouse Cortex and Hippocampus
Tsai, H., Taniguchi, S., Samoza, J., & Ridder, A. (2015) · Neuroscience Journal · doi:10.1155/2015/525369 · Cited by 40
Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer
Verma, S., Shankar, E., Chan, E. R., & Gupta, S. (2020) · Cells · doi:10.3390/cells9122535 · Cited by 38
A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells
Roggero, C. M., Jin, L., Cao, S., Sonavane, R., Kopplin, N. G., Ta, H. Q., Ekoue, D. N., Witwer, M., Ma, S., Liu, H., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01585-5 · Cited by 38
A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions
Raheem, O. A., Kulidjian, A., Wu, C., Jeong, Y. B., Yamaguchi, T., Smith, K. M., Goff, D. J., Leu, H. S., Morris, S., Cacalano, N. A., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-185 · Cited by 36
Molecular underpinnings of enzalutamide resistance
Preković, S., den Broeck, T. V., Linder, S., van Royen, M. E., Houtsmuller, A. B., Handle, F., Joniau, S., Zwart, W. T., & Claessens, F. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0136 · Cited by 37
Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
Kita, Y., Goto, T., Akamatsu, S., Yamasaki, T., Inoue, T., Ogawa, O., & Kobayashi, T. (2018) · Cancers · doi:10.3390/cancers10100345 · Cited by 40
Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy
Velasco, M. A. D., Kura, Y., Sakai, K., Hatanaka, Y., Davies, B. R., Campbell, H., Klein, S., Kim, Y. S., MacLeod, A. R., Sugimoto, K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.122688 · Cited by 37
Androgen receptor variants: RNA-based mechanisms and therapeutic targets
Tietz, K. T., & Dehm, S. M. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa089 · Cited by 36
ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
Kim, E. H., Cao, D., Mahajan, N. P., Andriole, G. L., & Mahajan, K. N. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa018 · Cited by 37
The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer
Liu, B., Sun, Y., Tang, M. M., Liang, C., Huang, C., Niu, Y., Wang, Z., & Chang, C. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02932-w · Cited by 36
Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy
Li, H., Zhang, Y., Li, D., Ma, X., Xu, K., Ding, B., Li, H., Wang, Z., Ouyang, W., Long, G., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.01.037 · Cited by 36
An overview of prostate cancer (PCa) diagnosis: Potential role of miRNAs
Bilal, M., Javaid, A., Amjad, F., Youssif, T. M. A., & Afzal, S. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101542 · Cited by 35
Melanoma Antigen-A11 (MAGE-A11) Enhances Transcriptional Activity by Linking Androgen Receptor Dimers
Minges, J. T., Su, S., Grossman, G., Blackwelder, A. J., POP, E. A., Mohler, J. L., & Wilson, E. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.428409 · Cited by 35
20(S)‐protopanaxadiol‐aglycone downregulation of the full‐length and splice variants of androgen receptor
Cao, B., Liu, X., Li, J., Liu, S., Qi, Y., Xiong, Z., Zhang, A., Wiese, T. E., Fu, X., Gu, J., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27754 · Cited by 35
Trigred motif 36 regulates neuroendocrine differentiation of prostate cancer via HK2 ubiquitination and GPx4 deficiency
Zhao, X., Zhou, T.-R., Wang, Y., Bao, M., Ni, C., Ding, L., Sun, S., Dong, H., Li, J., & Liang, C. (2023) · Cancer Science · doi:10.1111/cas.15763 · Cited by 34
Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
Sanford, M. (2013) · Drugs · doi:10.1007/s40265-013-0129-9 · Cited by 34
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
Gupta, E., Guthrie, T. H., & Tan, W. W. (2014) · BMC Urology · doi:10.1186/1471-2490-14-55 · Cited by 34
A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer
Dahiya, N. R., Chandrasekaran, B., Kolluru, V., Ankem, M. K., Damodaran, C., & Vadhanam, M. V. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22848 · Cited by 34
Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells
Recouvreux, M. V., Wu, B. J., Gao, A. C., Zonis, S., Chesnokova, V., Bhowmick, N. A., Chung, L. W. K., & Melmed, S. K. (2017) · Endocrinology · doi:10.1210/en.2016-1939 · Cited by 35
Identification of an oncogenic network with prognostic and therapeutic value in prostate cancer
Magani, F., Bray, E. R., Martinez, M. J., Zhao, N., Copello, V. A., Heidman, L. M., Peacock, S. O., Wiley, D. J., D’Urso, G., & Burnstein, K. L. (2018) · Molecular Systems Biology · doi:10.15252/msb.20188202 · Cited by 32
MDV3100 for the treatment of prostate cancer
Mukherji, D., Pezaro, C. J., & Bono, J. S. D. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.651125 · Cited by 33
Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer
Merseburger, A. S., Joaquim Bellmunt, B., Jenkins, C., Parker, C. C., Fitzpatrick, J. M., & on behalf of the European Treatment Practices Group. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0478 · Cited by 33
Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer
Eichholz, A., Ferraldeschi, R., Attard, G., & Bono, J. S. D. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.038 · Cited by 32
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer
Antonarakis, E. S., & Armstrong, A. J. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.24 · Cited by 32
Role of androgen receptor splice variants in prostate cancer metastasis
Xu, J., & Qiu, Y. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.08.003 · Cited by 32
Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1
Patel, R., Fleming, J., Mui, E. J., Loveridge, C. J., Repiščák, P., Blomme, A., Harle, V. J., Salji, M. J., Ahmad, I., Teo, K., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708347 · Cited by 30
Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer
Grivas, P. D., Robins, D. M., & Hussain, M. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.003 · Cited by 31
Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer
Asangani, I. A., Blair, I. A., Duyne, G. D. V., Hilser, V. J., Moiseenkova‐Bell, V. Y., Plymate, S. R., Sprenger, C. C. T., Wand, A. J., & Penning, T. M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.012411 · Cited by 34
The role of microRNAs in prostate cancer progression.
Lo, U., Yang, D., & Hsieh, J. (2013) · PubMed Central · doi:10.3978/j.issn.2223-4683.2013.08.01 · Cited by 31
Prolonged androgen deprivation leads to overexpression of calpain 2: Implications for prostate cancer progression
Liu, T., Mendes, D. E., & Berkman, C. E. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2196 · Cited by 31
Novel drugs targeting the androgen receptor pathway in prostate cancer
Mateo, J., Smith, A. D., Ong, M., & Bono, J. S. D. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9472-2 · Cited by 31
Androgen receptor variant 12 promotes migration and invasion by regulating MYLK in gastric cancer
Xia, N., Cui, J., Zhu, M., Xing, R., & Lu, Y. (2019) · The Journal of Pathology · doi:10.1002/path.5257 · Cited by 31
What is the pathophysiology of a hormone-resistant prostate tumour?
TOMBAL, B. F. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70163-0 · Cited by 30
Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer
Armstrong, K., Ahmad, I., Kalna, G., Tan, S. S., Edwards, J., Robson, C. N., & Leung, H. Y. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.367 · Cited by 30
Generation of a C57BL/6 MYC -Driven Mouse Model and Cell Line of Prostate Cancer
Ellis, L., Ku, S., Li, Q., Azabdaftari, G., Seliski, J., Olson, B. M., Netherby, C. S., Tang, D. G., Abrams, S. I., Goodrich, D. W., et al. (2016) · The Prostate · doi:10.1002/pros.23206 · Cited by 30
A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells
Zahn, M., Marienfeld, R. B., Melzner, I., Heinrich, J., Renner, B., Wegener, S., Mießner, A., Barth, T. F. E., Dorsch, K., Brüderlein, S., et al. (2017) · Blood · doi:10.1182/blood-2016-06-720516 · Cited by 30
Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer
Čulig, Z., & Santer, F. R. (2013) · Steroids · doi:10.1016/j.steroids.2013.04.012 · Cited by 29
Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer
Bernemann, C., Humberg, V., Thielen, B., Steinestel, J., Chen, X., Duensing, S. M., Schrader, A. J., & Boegemann, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4276 · Cited by 29
Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer
Zhang, K., Zhou, S., Wang, L., Wang, J., Zou, Q., Zhao, W., Fu, Q., & Fang, X. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071163 · Cited by 30
Androgen Receptor Dependence
Chaturvedi, A. P., & Dehm, S. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_15 · Cited by 32
Cancer genome sequencing: Understanding malignancy as a disease of the genome, its conformation, and its evolution
Patel, L. R., Nykter, M., Chen, K., & Zhang, W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.10.018 · Cited by 28
Transcript Levels of Androgen Receptor Variant AR-V1 or AR-V7 Do Not Predict Recurrence in Patients with Prostate Cancer at Indeterminate Risk for Progression
Zhao, H., Coram, M., Nolley, R., Reese, S. W., Young, S. R., & Peehl, D. M. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.08.014 · Cited by 28
The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cells
Xu, D., Lin, T., Zhang, C., Tsai, Y., Li, S., Zhang, J., Yin, M., Yeh, S., & Chang, C. (2011) · The Prostate · doi:10.1002/pros.21474 · Cited by 28
Presence of Androgen Receptor Variant in Neuronal Lipid Rafts
Garza-Contreras, J., Duong, P., Snyder, B., Schreihofer, D. A., & Cunningham, R. L. (2017) · eNeuro · doi:10.1523/eneuro.0109-17.2017 · Cited by 28
Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer
Thorek, D. L. J., Ku, A. T., Mitsiades, N., Veach, D. R., Watson, P. A., Metha, D., Strand, S., Sharma, S. K., Lewis, J. S., Abou, D. S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1521 · Cited by 27
Regulation of androgen receptor variants in prostate cancer
Zhu, Y., & Luo, J. (2020) · Asian journal of urology · doi:10.1016/j.ajur.2020.01.001 · Cited by 28
Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration‐resistant prostate cancer
Zhan, Y., Cao, B., Qi, Y., Liu, S., Zhang, Q., Zhou, W., Xu, D., Lu, H., Sartor, O. A., Kong, W., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28202 · Cited by 27
New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication
Gunter, J. H., Sarkar, P. L., Lubik, A. A., & Nelson, C. C. (2013) · International Journal of Cell Biology · doi:10.1155/2013/834684 · Cited by 27
Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
Makino, T., Izumi, K., & Mizokami, A. (2021) · Biomedicines · doi:10.3390/biomedicines9040414 · Cited by 31
Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells
Liang, J., Wang, L., Poluben, L., Nouri, M., Arai, S., Xie, L., Voznesensky, O. S., Cato, L., Yuan, X., Russo, J. W., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.013 · Cited by 26
A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer
Miller, K. J., Henry, I., Maylin, Z. R., Smith, C. P., Arunachalam, E., Pandha, H., & Asim, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1129140 · Cited by 28

Authors: Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Human Oncology and Pathogenesis Program,
Bioinformatics Core,
University of California, Los Angeles (US)
Howard Hughes Medical Institute (US)
Corresponding author: Sawyers, Charles L.
ORCID: Watson, Philip A.
Socci, Nicholas D.
Viale, Agnes
Kim, Kwanghee
Sawyers, Charles L.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2010-09-07
Volume: 107
Issue: 39
Pages: 16759-16765
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1012443107
PMC: PMC2947883
OpenAlex: W2083926838
Cited by: 639
References: 27
Citations by year: 2026: 8 · 2025: 19 · 2024: 22 · 2023: 33 · 2022: 25 · 2021: 26 · 2020: 43 · 2019: 33 · 2018: 36 · 2017: 43 · 2016: 63 · 2015: 48 · 2014: 64 · 2013: 65 · 2012: 53
FWCI: 46.52
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
Prostate Cancer Foundation
University of Washington
National Cancer Institute
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords: androgen receptor splice variants, castration-resistant prostate cancer, AR-V7, ligand-independent receptor activation, full-length androgen receptor, androgen withdrawal, antiandrogen resistance, enzalutamide, anchorage-independent growth, siRNA knockdown, prostate cancer cell lines, androgen receptor isoforms
MeSH terms: Amino Acid Sequence, Androgens, Animals, Castration, Disease Models, Animal, Exons, Humans, Male, Molecular Sequence Data, Prostatic Neoplasms, Receptors, Androgen, RNA, Messenger, Gene Expression Regulation, Neoplastic, Alternative Splicing, Protein Structure, Tertiary, Sequence Analysis, Protein, Cell Line, Tumor, Mice, Androgen Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks